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MALDI-TOF/TOF mass spectrometry
Laurent Bonesso1, Monique Piraud5, Céline Caruba1, Emmanuel Van Obberghen1,2,3,4, Raymond Mengual1†
and Charlotte Hinault1,2,3,4*†
Abstract
Background: Oligosaccharidoses, which belong to the lysosomal storage diseases, are inherited metabolic
disorders due to the absence or the loss of function of one of the enzymes involved in the catabolic pathway of
glycoproteins and indirectly of glycosphingolipids. This enzymatic deficiency typically results in the abnormal
accumulation of uncompletely degraded oligosaccharides in the urine. Since the clinical features of many of these
disorders are not specific for a single enzyme deficiency, unambiguous screening is critical to limit the number of
costly enzyme assays which otherwise must be performed.
Methods: Here we provide evidence for the advantages of using a MALDI-TOF/TOF (matrix-assisted laser desorption
ionization time-of-flight) mass spectrometric (MS) method for screening oligosaccharidoses. Urine samples from
previously diagnosed patients or from unaffected subjects were randomly divided into a training set and a blind
testing set. Samples were directly analyzed without prior treatment.
Results: The characteristic MS and MS/MS molecular profiles obtained allowed us to identify fucosidosis,
aspartylglucosaminuria, GM1 gangliosidosis, Sandhoff disease, α-mannosidosis, sialidosis and mucolipidoses type II
and III.
Conclusions: This method, which is easily run in less than 30 minutes, is performed in a single step, and is sensitive
and specific. Invaluable for clinical chemistry purposes this MALDI-TOF/TOF mass spectrometry procedure is
semi-automatizable and suitable for the urinary screening of oligosacharidoses.
Keywords: Oligosaccharidoses, Mass spectrometry, MALDI-TOF/TOF
Introduction
Oligosaccharidoses, also called glycoproteinoses, are inher-
ited metabolic diseases corresponding to a subset of lyso-
somal storage disorders resulting in deficient activity of one
of the lysosomal hydrolases involved in the degradation of
oligosaccharide components of glycoproteins. The glyco-
sidic groups can be either N-linked or O-linked. These dis-
eases are characterized by the abnormal accumulation of
intermediate oligosaccharides in tissues and body fluids and
by their excretion in the urine [1]. The metabolism of gly-
cosphingolipids and glycosaminoglycans can also be im-
paired and lead to accumulation of these macromolecules.
Oligosaccharidoses involve mainly the catabolic pathways
for N-linked-glycoprotein breakdown that are bidirectional
with sequential cleavages from both the reducing end of
the oligosaccharide released after proteolysis, and from the
non-reducing end (Additional file 1: Figure S1).
Oligosaccharidoses form a group of metabolic disor-
ders [2] including fucosidosis (α-L-fucosidase deficiency),
aspartylglucosaminuria (N-aspartyl-β-glucosaminidase de-
ficiency), sialidosis (formerly called mucolipidosis type I,
α-D-neuraminidase deficiency), GM1 gangliosidosis (β-D-
galactosidase deficiency), Sandhoff disease also called GM2
gangliosidosis variant O (N-acetyl-β-D-hexosaminidase de-
ficiency), α-mannosidosis (α-D-mannosidase deficiency)
and β-mannosidosis (β-D-mannosidase deficiency). Oligo-
saccharidoses also include mucolipidoses type II and III
(ML II and III), resulting from the deficiency of N-
acetylglucosaminyl-1-phosphotransferase. This enzyme is
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required to generate a mannose-6-phosphate residue, the
absence of which leads to incorrect addressing of hy-
drolases to the lysosomes [2]. All these diseases are
characterized by the urinary accumulation of specific
oligosaccharides (see Table 1) [3]. Note that abnormal
oligosaccharides are also excreted in galactosialidosis
due to neuraminidase and β-galactosidase deficiencies
resulting from a primary lack in a third lysosomal
protein, the bifunctional protein Protective Protein/
Cathepsin A [2].
The clinical signs of the different oligosaccharidoses
are variable from one disorder to another, but also in
terms of the severity among patients suffering from the
same disease. However, oligosaccharidoses usually share
some common clinical features including facial dysmorph-
ism and progressive mental retardation [4]. Oligosacchari-
doses can occur from early infant to adult age, and even at
the prenatal stage.
Like for other lysosomal storage disorders (mainly
mucopolysaccharidoses and sphingolipidoses), several tri-
als have been undertaken for specific treatments [5]. Since
oligosaccharidoses are rare diseases in humans, animal
models have been developed for the validation of different
therapeutic approaches, such as bone marrow transplant-
ation (BMT), enzyme replacement therapy (ERT), sub-
strate reduction therapy or cell transplant therapy [6-11].
More recently, gene therapy and pharmacological chaper-
ones for enzyme enhancement have been tested [12,13].
Nonspecific BMT has been conducted in patients affected
with aspartylglucosaminuria [14-16], fucosidosis [14,17],
sialidosis [18], alpha-mannosidosis [14,19,20] and GM1
gangliosidosis [21], with usually incomplete recovery of
the disease. Enzyme enhancement therapies have also re-
cently been considered in GM1 and GM2 patients [22-24].
Since clinical features in many of these disorders are
not characteristic for a single enzyme deficiency, effect-
ive screening is critical to limit the number of enzyme
assays which otherwise should be performed. Current
screening of oligosaccharidoses is routinely achieved on
urine of suspected patients by profiling oligosaccharides
and glycopeptides by thin layer chromatography (TLC)
on silica gel and by revealing them using sulfuric orcinol
[25]. Note that sialic acid-specific resorcinol staining can
be used in addition to sulfuric orcinol staining to im-
prove sialic residue detection. Testing oligosaccharidoses
in urine is a non-invasive procedure which is useful es-
pecially with newborn patients. However, TLC analysis
does not permit identification of the accumulated me-
tabolites. Indeed, the abnormal presence of spots with a
low retention factor is suggestive of an oligosaccharido-
sis. The diagnosis of the disorder can require a second
TLC to confirm superimposition of the considered pat-
tern with that from a patient affected with the incrimi-
nated oligosaccharidosis. Although TLC is technically
simple it is time-consuming.
Improvement of the diagnostic test requires the develop-
ment of more efficient and specific analytical methods.
Several approaches have been tested including high per-
formance liquid chromatography (HPLC) [26-28], but these
have not been widely introduced in clinical chemistry la-
boratories. Over the last years, mass spectrometry (MS) has
become the tool of choice for selective screening of inher-
ited metabolic diseases and has made a major impact on
detection strategies [29]. Different MS approaches have
Table 1 Urine samples used for MALDI-TOF/TOF analysis of oligosaccharides randomly divided into a training set and
a blind validation set
Number of samples
Disease Enzyme deficiency Urinary oligosaccharide (OS) detected
by TLC
Training
set
Validation
set
Total of
samples
Fucosidosis α-L-Fucosidase +++ (Fucosyl OS) 3 2 5
Aspartylglucosaminuria N-Aspartyl-β-glucosaminidase +++ (Glycoasparaginyl OS) 2 1 3
Sialidosis α-D-Neuraminidase +++ (Sialyl OS) 4 4 8
GM1 gangliosidosis β-D-galactosidase +++ (Galactosyl OS) 5 7 12
Sandhoff disease N-acetyl-β-D-hexasominidase A
and B
± (GlcNAc OS) 4 2 6
α-mannosidosis α-D-mannosidase +++ (Mannosyl OS) 7 4 11
Mucolipidose type II N-Acetylglusaminyl 1-Phospho-
transferase
ND (Sialyl OS) 6 1 7
Mucolipidose type III N-Acetylglusaminyl 1-Phospho-
transferase
ND (Sialyl OS) 4 2 6
Unaffected (control) none ND 6 30 36
Total 41 53 94
Number of urine samples from patients unaffected or previously diagnosed to be affected with oligosaccharidose (TLC: Thin Layer Chromatography revealed
using sulfuric orcinol, OS: oligosaccharides, GlcNAc: N-acetylglucosamine, +++: intensive spots, ±: weak spots, ND: not detectable).
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been described for oligosaccharidosis screening. However,
to the best of our knowledge, these methods necessitate
prior treatment of the urinary samples with derivatization
such as permethylation or PMP (3-methyl-1-phenyl-2-pyra-
zolin-5-one) processes usually combined with HPLC or GC
and confirmed by enzymatic digestion [3,30-32]. Although
derivatization procedures bring improvements in sensitivity,
these methods add procedures with possible sample deteri-
oration and contamination, thereby potentially decreasing
their benefits.
To improve the diagnosis of oligosaccharidoses, we
propose here a direct method using matrix-assisted
laser desorption/ionization (MALDI) and tandem mass
spectrometry to obtain a MS/MS signature. This semi-
automatizable approach is sensitive, specific and can be ap-
plied to the urinary screening of oligosaccharidoses.
Materials and methods
Patient samples
Urine samples were obtained from patients suspected of
oligosacharidoses, and were stored at -20°C until ana-
lysis. Some samples were from patients affected with
very rare oligosaccharide disorders, and were collected
at the time of diagnosis some 30 years ago. Suspected
patients, aged in majority between 1 month to 13 years
with some up to 60 years, were suffering from mild or
severe phenotypes with clinical signs most frequently in-
cluding facial dysmorphism, dysostosis multiplex, hepa-
tosplenomegaly, progressive neurodegeneration, deafness
and visual impairment.
Ninety-four urine samples were analyzed. Fifty-eight
were obtained from patients affected with various oligo-
saccharidoses. The diagnosis was ascertained in all cases
on the basis of an abnormal characteristic TLC oligosac-
charide pattern revealed using sulfuric orcinol [25] and
of the demonstration of the specific enzymatic deficiency
in serum and/or leukocytes and/or cultured skin fibro-
blasts (Laboratory of Hereditary Diseases of Metabolism,
East Center for Biology and Pathology, Civilian Hospices,
Lyon, France (57 cases), Biochemistry Laboratory,
University Hospital, Nice, France (1 fucosidosis case)).
Other urine samples from unaffected subjects (aged-
matched to pediatric patients) were from the two
laboratories. For mass spectrometry, samples were an-
alyzed in two different sets. The first set was used for
identification and characterization of the various MS/
MS patterns; the second one was blindly analyzed for
validation of the method (see Table 1).
Materials
DHB (2,5-dihydroxybenzoic acid) and 3-AQ (3-amino-
quinoline) matrices were purchased from Sigma-Aldrich
(St. Louis, MO). All other chemicals were obtained from
Merck (Darmstadt, Germany).
Sample preparation
After thawing in an ice-bath, the urine samples were
centrifuged for 5 min at 25.000 g at 4°C and the super-
natants were diluted 1:3 in ultra-pure water. 0.5 μl were
spotted on a MALDI 384 target plate ground steel with
2 μl of 3-AQ (15 g/l with 70% (v/v) of methanol, 1%
(v/v) of NaCl 0.9% (w/v) and 0.2% (v/v) trifluoroacetic
acid, TFA) for positive ion mode analysis and with 2 μl
of DHB (50 g/l with 50% (v/v) of acetonitrile) for nega-
tive ion mode analysis. These preparations were done in
triplicate and dried quickly with a hair-dryer.
Mass spectrometric analysis
All measurements were recorded on an Ultraflex III
MALDI-TOF/TOF (BrukerDaltonics, Bremen, Germany).
External calibration was performed by spotting 0.5 μL pep-
tide calibration standard II (BrukerDaltonics). All mass
spectra were generated by summing 1,000 laser shots for
reflectron ion mode, and 1,000 laser shots for the parent
mass and at least 1,000 laser shots for the fragments in the
lift mode. Laser power was adjusted between 15 and 30% of
its maximal intensity, using a 200-Hz smartbeam laser. MS
spectra were acquired in the reflectron positive ion mode
within a mass range from 300 to 2,000 Da and in the reflec-
tron negative ion mode within a mass range from 700 to
2,100 Da. Reflectron ion mode was chosen to obtain high
detection sensitivity and resolution. Mass accuracy was
about 14 ppm for 1347 Da. The FlexAnalysis version 3.0
and updated 3.4 provided by the manufacturer were applied
for data processing. The GlycoWorkbench version 2.1 was
used for the process of structure determination from mass
spectrometry data and to draw glycan structures.
Results
Set up of the screening method
Our overall aim was to develop an accurate, simple and
rapid method for the urinary screening of oligosacchari-
doses using MALDI-TOF/TOF mass spectrometry. To
characterize the MS and MS/MS profiles of a particular
disease and to identify the accumulated oligosaccharides,
we used a training set of urine samples from patients af-
fected with different oligosaccharidoses (Table 1).
To set up the screening method, we took advantage of
the relative tolerance for salt of MALDI mass spectrom-
etry to directly analyze urine samples without prior
treatment. As neutral glycans are able to ionize by cap-
ture of one sodium ion, we analyzed our samples in the
positive ion mode meaning that the pseudomolecular
ions detected correspond to [M +Na]+ [33]. Note that in
a salty medium, such as urine, oligosaccharides form ad-
ducts with sodium, but also with potassium resulting in
a weaker supplemental pseudomolecular ion, [M + K]+.
The latter is detected by a characteristic double peak
separated by a 16 atomic mass unit (amu) difference,
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which corresponds to a potassium mass minus a sodium
mass. Therefore, sodium salt was added to the sample
matrix to favor sodium adducts. We also worked in the
negative ion mode to detect sialylated glycans since the
major form of sialic acid residue in the acidic urine pH
is negatively charged. In this mode, the pseudomolecular
ions observed correspond to molecular ions that have
lost one proton, [M-H]−.
DHB and 3-AQ matrices are commonly used for gly-
can analysis by MALDI mass spectrometry [34-37]. We
tested both matrices in positive and negative ion modes
to optimize sample-matrix preparation to detect oligo-
saccharides without purification and derivatization pro-
cedures in urine samples. We adjusted our protocol
based on a previous study for which we had to detect
glycolipids (sialylated gangliosides and globosides) [38].
Both matrices allowed ionization in each mode. How-
ever, we obtained better signal intensity and fragmenta-
tion in the positive ion mode with 3-AQ matrix and in
the negative ion mode with DHB matrix. Thus, the
protocol has consisted in preparing each urinary sample
in triplicate with 3AQ and DHB matrices. We recorded
and analyzed MS data in reflectron positive and negative
ion modes, and achieved the MS/MS analyses on inten-
sive peaks for identification.
The MS/MS data do not provide absolute structure in-
formation for isomers such as N-acetylgalactosamine
(GalNAc) or N-acetylglucosamine (GlcNAc), which is
identified as N-acetylhexosamine (HexNAc). This is also
the case for glucose, mannose and galactose, which are
identified as hexoses. Predicted assignment of these
oligosaccharide structures has been represented on MS
spectra.
Analysis of the training set
We first analyzed urines from subjects not suffering
from oligosaccharidosis (controls). In positive ion mode,
we always observed three intensive peaks from pseudo-
molecular ions at m/z 429.2, 628.6 and 1148.5 as shown
on a representative MALDI-TOF MS spectrum (Figure 1A).
We performed a MALDI-TOF/TOF (MS/MS) analysis for
each of these ions with the goal to identify these com-
pounds. However, no chemical composition could be re-
lated (data not shown). In negative ion mode, we constantly
found peaks in the low molecular mass region m/z 700 to
1100 including pseudomolecular ions at m/z 728.9, 750.9,
886.8 and 1078.8, but no oligosaccharides could be identi-
fied (Figure 1E).
Analysis of urine from three patients affected with fucosi-
dosis revealed a major pseudomolecular ion at m/z 504.2
and a second less intense one at m/z 1079.4 (Figure 1B), for
which we were able to deduce the chemical composition.
Carbohydrate fragmentation generates several different
types of cleavage, and cationization can occur on different
atoms [33,39,40]. The MALDI-TOF/TOF analysis of the
parent ion at m/z 504.2 revealed a characteristic fragmenta-
tion with the more intense fragment ions at m/z 389.2,
358.2 and 289.1 (Figure 1C), corresponding respectively to
a loss of an asparaginyl residue, a loss of a fucosyl residue
and to a fragmentation inside the HexNAc cyclic form as
previously described ([39] Additional file 1: Figure S2).
Thus, the parent ion at m/z 504.2 corresponds to the [M+
Na]+ ion of the Fuc-HexNAc-Asn (fucosyl-GlcNAc-Aspara-
gine) oligosaccharide excreted in excess in urine of patients
suffering from fucosidosis. Similarly, the MS/MS spectrum
for the m/z 1079.5 parent ion revealed several specific frag-
ments, among which the most intense one at m/z 933.4
corresponding to a loss of a fucosyl residue (Figure 1D). In
negative-ion MS spectrum, we observed a peak at m/z
1518.5 with two weaker ones at m/z 1680.6 and 1883.7 for
which we were able to deduce the chemical composition
(Figure 1F), notably with the MS/MS analysis for the parent
ion at m/z 1518.5 (Figure 1G). These oligosaccharides do
not contain sialic acid, however they are detectable in nega-
tive mode thanks to the carboxyl group of asparagine.
Analysis of urine from two patients affected with
aspartylglucosaminuria revealed a pseudomolecular ion
at m/z 358.2 (Figure 2B). The MALDI-TOF/TOF ana-
lysis of the m/z 358.2 parent ion revealed a characteristic
fragmentation with the more intense fragment ions at
m/z 155.2 and 243.0 (Figure 2B), reflecting respectively a
loss of an HexNAc residue, and the fragmentation of an
asparaginyl residue as described above. This HexNAc-
Asn compound predicted to be GlcNAc-Asn is known
as the major stored compound in this disease (Figure 2A).
We were also able to reproducibly detect lower intensity
peaks at m/z 520.2, 811.3 and 885.3, which are expected to
be glycoasparagine compounds as shown in Figure 2A. The
negative-ion MS profile for urine from aspartylglucosami-
nuria affected patients showed two intensive peaks at m/z
787.2 and 809.2, corresponding respectively to [M-H]- and
[M-2H+Na]- forms of the same compound, with some
weaker peaks at m/z 1152.4, 1517.5 and 1882.6 (Figure 2C).
The MS/MS analysis of the parent ion at m/z 787.2 gave
characteristic fragments notably with the loss of a sialic
residue identified at m/z 495.9 and the sialic residue at m/z
289.8 (Figure 2D).
Analysis of urine from five GM1 gangliosidosis patients
revealed two major pseudomolecular ions found at m/z
933.3 and 1460.5 in addition to lower intensity ions at m/z
1095.4, 1298.5, 1663.6 and 1825.7 (Figure 3A). All these
peaks are separated either by a loss of 162 or 203 amu cor-
responding respectively to the loss of a hexose or an N-
acetylhexosamine residue (Figure 3A). Morever, the MS/
MS analysis on the more intense parent ions at m/z 933.3
(Figure 3B) and 1460.5 (Figure 3C) shows with confidence
the reproducible and characteristic fragmentation profile of
the major glycocompounds accumulated in urine from
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GM1 gangliosidosis patients. In negative ion mode, no
characteristic peak was observed on MS spectrum
(Figure 3D).
Analysis of urine from four patients affected with
Sandhoff disease revealed characteristic pseudomolecu-
lar ions at m/z 771.2, 1136.3 and 1339.4 with lower
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intensity ions at m/z 974.3 and 1542.4. All these peaks
are separated from each other by an amu difference cor-
responding to a hexose or a HexNAc residue (Figure 3E).
We were able to perform MS/MS on the three more in-
tense peaks at m/z 771.2 (Figure 3F), 1136.3 (Figure 3G)
and 1339.4 (Figure 3H) which showed a signature with
fragments typical for the identification of the Sandhoff dis-
ease. No characteristic peak was observed in negative-ion
MS spectrum for this disorder (Figure 3I).
Analysis of urine from seven patients affected with α-
mannosidosis revealed a major peak at m/z 568.2 with
additional peaks all separated by an amu difference cor-
responding to a hexose residue (Figure 4A). The MS/MS
spectrum of the m/z 568.2 ion corresponds to a trisac-
charide Hex-Hex-HexNAc with the specific peaks at m/
z 365.1 agreeing with the loss of the HexNAc residue
and at m/z 244.0 to the loss of two hexose residues
(Figure 4B). This trisaccharide is probably Man-Man-
GlcNac, which is the major compound described to
be accumulated in α-mannosidosis patients (2). No
characteristic peak was observed in negative-ion MS
spectrum (Figure 4C).
Analysis in positive ion mode of urine from four pa-
tients affected with sialidosis could reveal two weak
characteristic peaks at m/z 933.5 and 1460.6 (Figure 5A).
These two peaks are detected with higher intensity in urine
from GM1 gangliosidosis affected patients (Figure 3A).
Thus, the chemical structure of these ions corresponds to
the same oligosaccharides as in GM1 gangliosidosis, i.e.
oligosaccharides that have spontaneously lost their sialic
acid residues during ionization/fragmentation in positive
ion mode. Interestingly, in negative ion mode, the MS
spectrum showed a pseudomolecular ion at m/z 1200.4 and
less intense ions at m/z 1362.5, 1565.5, 1727.6 (Figure 5B).
Among them, those at m/z 1200.4 and 1727.6 correspond
to the oligosaccharides found in positive mode, with an
additional sialic acid residue. The biantennary-disialylated
oligosaccharide revealed three different peaks at m/z
2018.6, 2040.6 and 2056.5 corresponding respectively to
[M-H]-, [M-2H +Na]-, and [M-2H +K]- forms of the
compound (Figure 5B). The MS/MS profile for the parent
ion at m/z 1200.4, corresponding to the major sialylated
compound, gave characteristic fragments with the sialic
residue at m/z 289.6 (Figure 5C). Thus, the negative ion
mode analysis allowed to detect sialylated oligosaccha-
rides, which is not the case with the positive ion mode.
Finally, analysis of urine from six patients affected with
MLII and four MLIII revealed MS and MS/MS spectra,
in positive and negative ion modes, overall comparable
from those obtained with urine from sialidosis affected
patients (Figure 5). For some patients, biantennary-
disialylated oligosaccharides were less detectable than for
sialidosis. No urine from galactosialidosis affected patients
could be analyzed, because of the rarity of the disease, but
a similar pattern can be anticipated.
Analysis of the validation set
The MS and MS/MS analyses performed on the training
set of urine samples from patients known to suffer from
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various oligosaccharidoses enabled to identify character-
istic accumulated oligosaccharides in urine and typical
patterns that are useful for the diagnosis of new cases.
The specificity of the method was then validated by
blind analysis of a series of fifty-three samples including
urine from control and oligosacharidosis affected pa-
tients (validation set, Table 1). Considering the rarity of
these disorders, we have on purpose not taken into ac-
count the severity of the pathology when urine samples
were randomly divided into the training and validation
sets. The objective was to develop a specific assay allow-
ing us to determine the predictive value of our protocol
for oligosaccharidose screening in any circumstances.
Specific MS and MS/MS profiles of fucosidosis (2 cases),
aspartylglucosaminuria (1 case), GM1 gangliosidosis
(7 cases), Sandhoff disease (2 cases) and alpha-
mannosidosis (4 cases) were identified from the above
described characteristic patterns. Seven profiles corre-
sponding to sialidosis/MLII/MLIII profiles were also
recognized. After removal of patient anonymity, all the
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profiles observed were in perfect agreement with the previ-
ous diagnosis. None of the thirty control subjects showed
any of the peaks characteristic for oligosaccharidosis.
In summary, analysis of ninety-four urine samples, with
the training and the validation sets, made it possible to
identify fifty-eight characteristic pathological patterns from
fifty-eight urine samples previously diagnosed by TLC/en-
zymatic assays for different oligosaccharidoses.
Discussion
The clinical diagnosis of oligosaccharidoses can be chal-
lenging because of the great variability in symptoms. The
recent development of specific therapies for lysosomal
storage disorders, and particularly for oligosaccharidoses,
raises the medical request for oligosaccharidosis screening
in order to offer the opportunity to the patient to benefit
from a precise diagnosis and hence the appropriate
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treatment. To date, screening is commonly performed by
TLC [25,27] in laboratories working in the field of inborn
errors of metabolism. This time-consuming method per-
mits to evoke a number of possibilities for the suspected
oligosaccharidosis, but in most cases the precise diagnosis
is subsequently confirmed by enzymatic analysis and in
some cases by molecular biology. Efforts to improve the
oligosaccharidosis screening have been achieved using
mass spectrometry. For instance, the group of Michalski
developed a strategy combining three different approaches
with MALDI-TOF-MS and GC-MS after permethylation
and enzymatic digestions to identify the glycocompounds
accumulated in urine [30]. More recently, a method using
PMP derivatization combined with LC-MS/MS has been
adapted to screen oligosaccharidoses by selected reaction
monitoring MS, and it revealed specific patterns corre-
sponding to each disorder [32]. While our report was
under review, Xia et al. also reported that MALDI-TOF-
MS could be used for the diagnosis of lysosomal storage
diseases after sequential passage over different columns and
permethylation of urine samples [41]. These approaches
used laborious and expensive pre-analytic treatment of
urines mainly to detect sialylated oligosaccharides and
glycoamino acids. Indeed, these chemical stabilization pro-
cedures are used to increase ionization efficiency of oligo-
saccharides and to prevent spontaneous loss of labile sialic
acid residues during ionization and fragmentation.
The screening strategy that we present here with
MALDI/TOF-TOF tandem mass spectrometry offers
multiple advantages. These include the analysis in a
short time on a very small amount of urine with an op-
timized and simple sample-matrix-preparation proced-
ure and a high specificity and sensitivity of detection.
In positive ion mode we are able to directly detect and
identify complex oligosaccharides and glycoamino
acids in urines from oligosaccharidosis affected pa-
tients without any sample preparation. Importantly,
using the negative ion mode we revealed negatively
charged sialylated oligosaccharides, which is not possible
with the positive ion mode. However, the chemical struc-
ture of sialyl-oligosaccharides, with the presence of a carb-
oxyl group at the anomeric carbon of sialic acid, easily
explains the lack of signal of sialyl-oligosaccharides in posi-
tive mode, and the readily formed [M-H]- ions in MS/MS
negative mode. Note that we have tested matrices other
than DHB, such as 9-aminoacridine or 1,5-diaminonaphta-
lene, without better reliable results in this mode (data not
shown). Thus, only the negative ion mode is suitable to de-
tect directly sialylated oligosaccharides.
Urine is known to contain some simple oligosaccharides
but their excretion levels depend on various physiological
circumstances [30]. Indeed, it has previously been reported
in chemically derivated urine (e.g. permethylated urines)
that some oligosaccharides can be detected by mass
spectrometry [30,41]. In our study, we found in urines from
healthy subjects, with a similar abundant pattern, a set of
intensive peaks for which no chemical composition could
be identified. To avoid misinterpretation, we have analyzed
additional samples (n > 50), and we obtained the same kind
of profile as previously found for the controls without oli-
gosaccharides identified from the more intensive peaks.
Therefore, some oligosaccharides might be present in the
urines from unaffected subjects but in very low abundance
compared to the one accumulated in pathological urines,
and being therefore undetectable by our method without
pre-analytical treatment.
The MALDI-TOF/TOF analysis presents a relative
simplicity of spectral interpretation directly obtained
from native urine oligosaccharides with singly charged
ions. It provides a reliable oligosaccharide pattern, with
a specific MS and MS/MS signature for each oligosac-
charidosis resulting in a positive argument for the
diagnosis of these disorders when present, and an ar-
gument for the exclusion of these disorders when
absent. Indeed, it gives a structural analysis enabling
the identification of the chemical composition (except
for isomers as mentioned above) and of the structure
of the accumulated oligosaccharides characteristic of
each disease. This approach has a very high sensitivity
and resolution permitting the detection of all the char-
acteristic compounds for each disorder, independent of
patient age and/or disease severity. Moreover, for ana-
lysis of pediatric patients the scant volume of the sam-
ples is a limitation for several screening procedures.
Importantly, the protocol developed here stands out as
it requires a minimal volume of urine (10 μl) and can
be easily performed in less than 30 min without expen-
sive sample preparation.
Precise quantification of the amount of accumulated
oligosaccharides in each disease could be useful for the
follow-up of the treatment and would require an internal
standard, possibly deuterated. In this case, the results
would require to be reported to the creatinine level,
which is a variable parameter measuring the urine con-
centration often used as a correcting factor in many
analytical methods involving urine. In our study, we per-
formed a run of samples with creatinine concentrations
standardized to 1 nmol/l. We observed the same MS
profile compared to results obtained without creatinine
correction (data not shown).
Despite the relative low frequency of these diseases,
we had the possibility to study between 3 to 12 samples
for each oligosaccharidosis. Each sample was analyzed in
triplicate on three different days, in order to estimate
the intra- and the inter-assay reproducibility, but no dif-
ference was found. After identification of the profiles on
the samples of the training set, the method was validated
by blindly analyzing a second set of samples, which
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renders our study particularly original and powerful. No
false negative results were noticed. Thus, the reproducibility
and specificity of our approach allowed us to characterize
with confidence eight different oligosaccharidoses with
urinary accumulation of uncompletely degraded oligosac-
charides. The same oligosaccharide pattern (mainly sialyl-
oligosaccharides) was observed in sialidoses, ML II and ML
III. Therefore, we have re-analyzed all our samples from pa-
tients suffering from sialidosis, ML II and ML III after the
training and validation analyses. We compared their MS
spectra in terms of peak intensity and we were able to rank
them in ascending order MLIII <MLII < sialidosis (data not
shown). ML II and ML III could not be detected by the
TLC oligosaccharide method using sulfuric orcinol staining.
These diseases were distinguished and diagnosed by
additional enzymatic tests, which are always requested
for assessing the correct diagnosis, whatever the oligo-
saccharide analysis method used. Note that abnormal
sialyl-oligosaccharides would have been probably re-
vealed with chlorhydric resorcinol staining of TLC
plates. Therefore, our method brings more information
than the prior TLC method using orcinol.
In conclusion, the strategy we developed here with the
MALDI-TOF/TOF mass spectrometry for the urinary
screening and identification of oligosaccharidoses is ac-
curate and performed in a single rapid step. Hence, this
screening method of these metabolic disorders could be
easily adapted in clinical chemistry laboratories equipped
with a MALDI-TOF/TOF mass spectrometric apparatus.
Interestingly, this method could further be adjusted to
other kinds of samples (amniotic fluid, ascites and maybe
serum or cultured cells) and to other lysosomal storage dis-
eases (glycosphingolipidoses, mucopolysaccharidoses).
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